AAPG vs AZN

AAPG's Piotroski F-Score of 4/9 indicates weak financial health, with no Altman Z-Score available to assess bankruptcy risk. The company exhibits severe profitability issues, with a negative profit margin of -296.77% and ROE of -159.65%, alongside a 71.6% YoY revenue decline. Despite a high gross margin of 90.87%, the business is not generating sustainable earnings. The stock trades at a premium valuation (Price/Book: 79.25) with no intrinsic value or Graham Number, suggesting speculative pricing. Analysts rate it a 'strong_buy' with a target of $49.14, but this is not supported by fundamentals.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.